Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;234(9):14721-14733.
doi: 10.1002/jcp.28230. Epub 2019 Jan 29.

Targeted-nanoliposomal combretastatin A4 (CA-4) as an efficient antivascular candidate in the metastatic cancer treatment

Maryam Ebrahimi Nik  1   2 , Amir Abbas Momtazi-Borojeni  1   3 , Parvin Zamani  1   3 , Jamshid Gholizadeh Navashenaq  2   4 , Mehrdad Iranshahi  5 , Mahmoud Reza Jaafari  5   6 , Bizhan Malaekeh-Nikouei  1
Affiliations
Review

Targeted-nanoliposomal combretastatin A4 (CA-4) as an efficient antivascular candidate in the metastatic cancer treatment

Maryam Ebrahimi Nik et al. J Cell Physiol. 2019 Sep.

Abstract

A number of antiangiogenic drugs have been approved by the Food and Drug Administration which are used in cancer therapy, and variety of other agents in several stages of clinical development or in preclinical assessment. Among these, combretastatin A4 (CA-4) is an under-researched inhibitor of angiogenesis that shows potential activity in the treatment of advanced tumors with migration capacity. However, its clinical application has been limited due to poor water solubility, low bioavailability, rapid metabolism, and systemic elimination. During the last decade, numerous investigations have been done to overcome these problems by using different CA-4 delivery systems or developing produgs of CA-4 or its structural analogs. Nevertheless, these strategies could not be efficient out of the undesired side effects on normal tissues. Nanoliposomal CA-4 not only benefits from the advantage of using liposomal drugs as opposed to free drugs but also can accumulate in the tumor site via specific targeting ligands, which leads to efficient targeting and enhancement of bioavailability. To the best of our knowledge, we consider an important attempt to understand different factors that might influence the CA-4 loading and release pattern of liposomes and the consequent results in tumor therapy. In this review, we shed light on various studied liposomal CA-4 formulations showing application thereof in cancer treatment.

Keywords: antiangiogenesis; cancer; combretastatin A4; nanoliposome.

PubMed Disclaimer

References

REFERENCES
    1. Alexis, F., Pridgen, E. M., Langer, R., & Farokhzad, O. C. (2010). Nanoparticle technologies for cancer therapy. In M. Schafer-Korting (Ed.), Drug Delivery (pp. 55-86). Springer.
    1. Allen, T. M., & Cullis, P. R. (2004). Drug delivery systems: Entering the mainstream. Science, 303(5665), 1818-1822.
    1. Amanolahi, F., Mohammadi, A., Golami, L., & Malaekeh-Nikouei, B. (2018). Curcumin improved liposomal mitomycin-induced cell toxicity in bladder cancer cell. Nanomedicine Journal, 5(4), 235-244.
    1. Amin, M., Badiee, A., & Jaafari, M. R. (2013). Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas. International Journal of Pharmaceutics, 458(2), 324-333.
    1. Amin, M., Jaafari, M. R., & Tafaghodi, M. (2009). Impact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbits. Colloids and Surfaces B: Biointerfaces, 74(1), 225-229.

LinkOut - more resources